Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

PHASE3TerminatedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

December 21, 2020

Study Completion Date

July 1, 2021

Conditions
Age-Related Macular Degeneration
Interventions
BIOLOGICAL

Brolucizumab

6 mg/0.05mL solution for intravitreal injection

BIOLOGICAL

Aflibercept

2 mg/0.05mL solution for intravitreal injection

Trial Locations (61)

13224

Novartis Investigative Site, Syracuse

19107

Novartis Investigative Site, Philadelphia

20602

Novartis Investigative Site, Waldorf

22031

Novartis Investigative Site, Fairfax

28210

Novartis Investigative Site, Charlotte

30060

Novartis Investigative Site, Marietta

32503

Novartis Investigative Site, Pensacola

32757

Novartis Investigative Site, Mt. Dora

33064

Novartis Investigative Site, Deerfield Beach

33136

Novartis Investigative Site, Miami

33308

Novartis Investigative Site, Fort Lauderdale

33711

Novartis Investigative Site, St. Petersburg

34994

Novartis Investigative Site, Stuart

38138

Novartis Investigative Site, Germantown

44122

Novartis Investigative Site, Cleveland

45014

Novartis Investigative Site, Fairfield

48073

Novartis Investigative Site, Royal Oak

50266

Novartis Investigative Site, West Des Moines

60187

Novartis Investigative Site, Wheaton

63110

Novartis Investigative Site, St Louis

66215

Novartis Investigative Site, Lenexa

71291

Novartis Investigative Site, West Monroe

75701

Novartis Investigative Site, Tyler

76102

Novartis Investigative Site, Fort Worth

76104

Novartis Investigative Site, Fort Worth

77030

Novartis Investigative Site, Houston

78240

Novartis Investigative Site, San Antonio

78550

Novartis Investigative Site, Harlingen

78705

Novartis Investigative Site, Austin

78731

Novartis Investigative Site, Austin

78793

Novartis Investigative Site, Austin

79606

Novartis Investigative Site, Abilene

80401

Novartis Investigative Site, Golden

80909

Novartis Investigative Site, Colorado Springs

85016

Novartis Investigative Site, Phoenix

85020

Novartis Investigative Site, Phoenix

85053

Novartis Investigative Site, Phoenix

89144

Novartis Investigative Site, Las Vegas

89502

Novartis Investigative Site, Reno

90211

Novartis Investigative Site, Beverly Hills

92374

Novartis Investigative Site, Redlands

92647

Novartis Investigative Site, Huntington Beach

93036

Novartis Investigative Site, Oxnard

93103

Novartis Investigative Site, Santa Barbara

94040

Novartis Investigative Site, Mountain View

94107

Novartis Investigative Site, San Francisco

94303

Novartis Investigative Site, Palo Alto

94609

Novartis Investigative Site, Oakland

95403

Novartis Investigative Site, Kingston

95841

Novartis Investigative Site, Sacramento

96701

Novartis Investigative Site, ‘Aiea

97401

Novartis Investigative Site, Eugene

99204

Novartis Investigative Site, Spokane

33912-7125

Novartis Investigative Site, Fort Myers

70115-8139

Novartis Investigative Site, New Orleans

02111

Novartis Investigative Site, Boston

02114

Novartis Investigative Site, Boston

01107

Novartis Investigative Site, Springfield

07003

Novartis Investigative Site, Bloomfield

08755

Novartis Investigative Site, Toms River

00612

Novartis Investigative Site, Arecibo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY